Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy
Clinical Pharmacology & Therapeutics2019Vol. 106(4), pp. 726–733
Citations Over TimeTop 1% of 2019 papers
Zeruesenay Desta, Roseann S. Gammal, Li Gong, Michelle Whirl‐Carrillo, Aditya H. Gaur, Chonlaphat Sukasem, Jennifer Hockings, Alan L. Myers, Marelize Swart, Rachel F. Tyndale, Collen Masimirembwa, Otito F. Iwuchukwu, Sanika Chirwa, Jeffrey L. Lennox, Andrea Gaedigk, Teri E. Klein, David W. Haas
Abstract
The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.
Related Papers
- → Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry(2019)63 cited
- → CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans(2011)49 cited
- → CYP2B6Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port‐au‐Prince, Haiti(2009)39 cited
- → Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers(2019)15 cited
- → Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers(2022)7 cited